Drugs used for diabetic patients could decrease the risk of Parkinson’s, researchers find
The prevention and treatment strategies for the progressive neurological disease just got better, thanks to new Norwegian study suggesting that glitazones (GTZs or thiazolidinediones ), substances used in treating type 2 diabetes, could significantly decrease the risk Parkinson’s disease.
The conclusions came after Dr. Charalampos Tzoulis, from the University of Bergen in Norway, and team analyzed over 100 million drug prescriptions from the Norwegian Prescription Database. Te study took place between 2005 and 2014. As a result, patients using GTZs were found to be less likely the ones to develop Parkinson’s, by 28 per cent, as researchers assume GTZs improve the function of mitochondria.
The findings were recently published in the Movement Disorders journal.
Nevertheless, further studies are needed to investigate the exact mechanisms behind the discovery and in order to generalize the results to people that do not have type 2 diabetes.
Parkinson’s disease is a condition that yearly affects more than 60.000 people in the U.S.